Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17253517 | Enzymes Entrapped in Organopolysiloxane Matrix for Treating Intestinal Diseases | December 2020 | March 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 16973530 | DELAMANID-CONTAINING COMPOSITION | December 2020 | January 2025 | Abandon | 50 | 4 | 0 | Yes | Yes |
| 17104240 | HAIR TREATMENT COMPOSITIONS, KITS, AND METHODS OF USE | November 2020 | February 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17074152 | ANTIOXIDANT COMPLEX AND COMPOSITION FOR FORMING SAME | October 2020 | June 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17041635 | LENALIDOMIDE GASTRO-RETENTIVE SUSTAINED-RELEASE TABLET AND PREPARATION METHOD THEREOF | September 2020 | November 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16978693 | PICOLINAMIDES AS FUNGICIDES | September 2020 | October 2024 | Abandon | 49 | 2 | 2 | Yes | No |
| 16983232 | SHEET FOR COVERING WOUND, AND METHOD FOR COVERING WOUND | August 2020 | May 2025 | Abandon | 57 | 4 | 1 | No | No |
| 16932470 | OPIOID RECEPTOR MODULATOR DOSAGE FORMULATIONS | July 2020 | February 2022 | Abandon | 19 | 1 | 1 | No | No |
| 16918538 | BIMODAL RELEASE ONDANSETRON TABLETS AND METHODS OF TREATING NAUSEA AND VOMITING | July 2020 | September 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16916421 | FORMULATIONS OF RIFAXIMIN AND USES THEREOF | June 2020 | May 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16772273 | NOVEL TERPOLYMERS AND THEIR USE IN PHARMACEUTICAL DOSAGE FORMS | June 2020 | February 2024 | Allow | 44 | 2 | 1 | No | No |
| 16841125 | IMMOBILISING BIOLOGICAL ENTITIES | April 2020 | May 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16753790 | METHOD OF PRODUCTION OF A BRANCHED ORGANOSILICONE POLYMEROUS POLYNUCLEAR ADSORBENT OF HIGH MOLECULAR TOXINS AND THIS ADSORBENT | April 2020 | June 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16833606 | METHODS AND COMPOSITIONS FOR WHITENING TEETH | March 2020 | March 2023 | Abandon | 35 | 1 | 0 | No | No |
| 16830904 | BEVERAGES FOR LOWERING BLOOD PRESSURE | March 2020 | April 2022 | Abandon | 25 | 1 | 1 | Yes | No |
| 16646336 | METHOD FOR PREPARING A SOLID DOSAGE FORM COMPRISING ANTIBODIES BY WET GRANULATION, EXTRUSION AND SPHERONIZATION | March 2020 | May 2025 | Allow | 60 | 2 | 1 | Yes | Yes |
| 16645529 | A Novel Green Micro-Emulsion for Controlling Fungal Wilt Diseases | March 2020 | April 2022 | Abandon | 25 | 0 | 2 | No | No |
| 16797189 | COMPOSITIONS AND METHODS FOR DELIVERING DRUGS TO A VESSEL WALL | February 2020 | December 2021 | Allow | 22 | 2 | 1 | No | No |
| 16640594 | ANHYDROUS ANTIPERSPIRANT AEROSOL COMPOSITION | February 2020 | March 2024 | Allow | 49 | 6 | 1 | Yes | Yes |
| 16751521 | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists | January 2020 | August 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16630219 | Method of Increasing Epithelial Permeability Using Nanoparticles | January 2020 | February 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16735009 | Tellurium Nanowires with Anticancer Properties Synthesized by Green Chemistry | January 2020 | December 2023 | Allow | 47 | 2 | 1 | Yes | Yes |
| 16733360 | COMPOSITIONS AND REAGENTS FOR ION BEAM IMAGING | January 2020 | April 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16728296 | STERILE LIQUID COMPOSITION FOR FILLING WRINKLES | December 2019 | June 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16621309 | COMBINATION AND USES AND TREATMENTS THEREOF | December 2019 | June 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16706999 | MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS WITH ENHANCED STABILITY | December 2019 | May 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16617940 | WATER-IN-OIL EMULSION COMPOSITION | November 2019 | November 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16697718 | COMBINED ODOR ABSORPTION AND INSECT REPELLENT COMPOSITIONS, TREATMENTS, AND METHODS OF USE | November 2019 | April 2021 | Abandon | 17 | 2 | 0 | Yes | No |
| 16615969 | STERILIZABLE PRE-FILLED PHARMACEUTICAL PACKAGES COMPRISING A LIQUID FORMULATION OF A VEGF-ANTAGONIST | November 2019 | March 2024 | Abandon | 52 | 2 | 1 | Yes | No |
| 16686109 | ANTIMICROBIAL GUANIDINIUM AND THIOURONIUM FUNCTIONALIZED POLYMERS | November 2019 | December 2020 | Allow | 13 | 2 | 0 | Yes | No |
| 16686111 | ANTIMICROBIAL GUANIDINIUM AND THIOURONIUM FUNCTIONALIZED POLYMERS | November 2019 | December 2022 | Allow | 37 | 1 | 1 | No | No |
| 16686069 | THERAPEUTIC NANOPARTICLES ENCAPSULATING TERPENOIDS AND/OR CANNABINOIDS | November 2019 | May 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16668529 | IMPLANT FOR SUBCUTANEOUS IMPLANTATION | October 2019 | September 2021 | Abandon | 23 | 0 | 1 | No | No |
| 16653595 | POLYELECTROLYTE-LAYER FORMING BLOCK COPOLYMERS AND COMPOSITIONS AND USES THEREOF | October 2019 | September 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16604078 | COLD-WATER-DISPERSIBLE CHEMICAL DELIVERY SYSTEM | October 2019 | March 2025 | Allow | 60 | 8 | 1 | Yes | No |
| 16588010 | MULTI-DRUG-LOADING-SITE, HIGH DRUG-LOADING CAPACITY LIGAND-DRUG CONJUGATE | September 2019 | September 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16583903 | PHARMACEUTICAL FORMULATIONS OF NAPROXEN FOR SOFT GEL ENCAPSULATION AND COMBINATIONS THEREOF | September 2019 | October 2023 | Allow | 48 | 6 | 0 | Yes | No |
| 16496559 | COMPOSITIONS FOR TREATING PERIODONTAL DISEASES | September 2019 | October 2024 | Abandon | 60 | 7 | 1 | Yes | No |
| 16577007 | SOFT CHEWS WITH LOW WATER ACTIVITY AND METHODS OF MANUFACTURING SAME | September 2019 | September 2024 | Allow | 60 | 7 | 1 | Yes | No |
| 16495749 | BIOSOURCED GELLED COMPOSITION OF HYDROCARBON OIL AND GELLING POLYMER | September 2019 | April 2024 | Allow | 55 | 6 | 1 | Yes | No |
| 16569909 | STABLE MULTIPARTICULATE PHARMACEUTICAL COMPOSITION OF ROSUVASTATIN | September 2019 | September 2024 | Abandon | 60 | 4 | 1 | No | Yes |
| 16569275 | POLYMORPHIC MIXTURE OF RIFAXIMIN AND ITS USE FOR THE PREPARATION OF SOLID FORMULATIONS | September 2019 | October 2020 | Allow | 14 | 1 | 0 | No | No |
| 16567852 | POLYMORPHIC MIXTURE OF RIFAXIMIN AND ITS USE FOR THE PREPARATION OF SOLID FORMULATIONS | September 2019 | March 2020 | Allow | 6 | 0 | 0 | No | No |
| 16566237 | METHODS OF INCREASING LACRIMAL PROTEINS | September 2019 | October 2021 | Allow | 25 | 2 | 0 | Yes | No |
| 16566439 | Cold Process Emulsifier Compositions | September 2019 | November 2023 | Abandon | 50 | 6 | 1 | Yes | No |
| 16566624 | OPHTHALMIC TREATMENT COMPOSITION AND VEHICLE FOR DELIVERY OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTIC AGENTS | September 2019 | July 2022 | Abandon | 35 | 1 | 2 | No | No |
| 16556789 | Hydrogen-containing composition for ameliorating depressive symptom | August 2019 | January 2024 | Abandon | 52 | 5 | 2 | No | No |
| 16555669 | PHARMACEUTICAL FORMULATION AND SYSTEM AND METHOD FOR DELIVERY | August 2019 | February 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16489609 | ZWITTERIONIC DENDRITIC AMPHIPHILES, ZWITTERIONIC DENDRIMERS, ZWITTERIONIC TELODENDRIMERS, NANOCARRIERS COMPRISING SAME, AND METHODS OF MAKING AND USING SAME | August 2019 | December 2021 | Abandon | 27 | 4 | 1 | Yes | No |
| 16531969 | TOPICAL OLEAGINOUS COMPOSITIONS | August 2019 | December 2021 | Abandon | 28 | 2 | 1 | No | No |
| 16522739 | PERSONAL CLEANSING COMPOSITIONS, METHODS AND USES | July 2019 | March 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16522069 | TWO-STEP LONG-WEAR COSMETIC SYSTEM | July 2019 | August 2022 | Allow | 37 | 4 | 1 | No | No |
| 16478789 | TELODENDRIMERS WITH RIBOFLAVIN MOIETIES AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | July 2019 | February 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16475894 | MICROMOTORS AND NANOMOTORS FOR GASTROINTESTINAL DIAGNOSIS AND TREATMENT APPLICATIONS | July 2019 | February 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16474435 | METHOD FOR MANUFACTURING COATING FILM BY ELECTROSTATIC SPRAYING | June 2019 | October 2022 | Allow | 40 | 3 | 1 | No | No |
| 16472669 | SILICONE-IN-WATER COSMETIC | June 2019 | April 2022 | Abandon | 34 | 2 | 1 | No | No |
| 16469699 | HEAVY METAL-FREE CALCIUM HYDROXIDE-BASED ACTIVE SUBSTANCE | June 2019 | November 2022 | Abandon | 41 | 2 | 1 | Yes | No |
| 16469769 | NEUTRALIZING VENOMOUS BIOMACROMOLECULES | June 2019 | May 2023 | Abandon | 47 | 3 | 1 | No | No |
| 16439694 | PARTICLES FOR DELIVERY OF BIOMOLECULES | June 2019 | March 2023 | Abandon | 45 | 2 | 2 | No | No |
| 16468199 | PH-RESPONSIVE POLYMER AND DRUG DELIVERY SYSTEM | June 2019 | November 2023 | Allow | 53 | 4 | 1 | Yes | Yes |
| 16467761 | LIP COMPOSITION IN THE FORM OF A LIQUID INVERSE EMULSION | June 2019 | July 2022 | Allow | 37 | 2 | 1 | No | No |
| 16465009 | HARD CAPSULE SHOWING IMPROVED DEPOSITION OF GELLING ADJUVANT AND METHOD FOR PREPARATION THEREOF | May 2019 | December 2021 | Allow | 31 | 2 | 1 | Yes | No |
| 16462401 | METHOD FOR PRODUCING COATING FILM FOR COSMETIC PREPARATION | May 2019 | August 2022 | Abandon | 39 | 4 | 0 | Yes | Yes |
| 16401559 | TOPICAL APPLICATION OF MEDICAL CANNABIS | May 2019 | February 2023 | Abandon | 45 | 5 | 1 | Yes | No |
| 16391430 | FILM DOSAGE FORMS CONTAINING AMORPHOUS ACTIVE AGENTS | April 2019 | June 2025 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 16374850 | ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME | April 2019 | July 2022 | Abandon | 40 | 2 | 1 | No | No |
| 16375429 | PVP Coated Tellurium Nanorods with Antibacterial and Anticancer Properties | April 2019 | December 2023 | Abandon | 57 | 6 | 1 | No | No |
| 16367499 | COSMETIC MINERAL SUNSCREEN COMPOSITIONS FOR SKIN | March 2019 | October 2021 | Abandon | 30 | 4 | 1 | Yes | Yes |
| 16336994 | Biodegradable, Antioxidant, Thermally Responsive Injectable Hydrogel and Uses Therefor | March 2019 | October 2022 | Allow | 43 | 4 | 1 | Yes | No |
| 16335569 | ORGANIC UV BLOCKER-SUPPORTED SILICA AEROGEL COMPOSITE | March 2019 | April 2021 | Abandon | 25 | 2 | 0 | No | No |
| 16335109 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | March 2019 | June 2021 | Abandon | 27 | 2 | 1 | No | No |
| 16356990 | TIOPRONIN ORAL COMPOSITION | March 2019 | January 2021 | Abandon | 22 | 2 | 0 | Yes | No |
| 16296906 | IMMOBILISING BIOLOGICAL ENTITIES | March 2019 | August 2020 | Abandon | 17 | 0 | 1 | No | No |
| 16291914 | METHODS FOR APPLYING A BIOACTIVE COATING ONTO A SURFACE OF AN IMPLANT | March 2019 | January 2021 | Allow | 22 | 1 | 1 | No | No |
| 16272229 | COSMETIC POWDER COMPOSITIONS PROVIDING SKIN SMOOTHING AND RADIANT OPTICAL EFFECT | February 2019 | October 2023 | Abandon | 56 | 4 | 1 | No | Yes |
| 16264890 | HYDROPHILIC NANOSTRUCTURED MEMBRANE ACTIVE ANTIMICROBIALS WITH HIGH ACTIVITY, SELECTIVITY AND BIODEGRADABILITY | February 2019 | March 2022 | Allow | 38 | 2 | 1 | Yes | No |
| 16322379 | NANOTECHNOLOGY-BASED HEMOSTATIC DRESSINGS | January 2019 | September 2022 | Allow | 44 | 4 | 1 | Yes | No |
| 16316390 | ORAL GASTRORETENTIVE FORMULATIONS AND USES THEREOF | January 2019 | March 2023 | Abandon | 50 | 3 | 1 | Yes | No |
| 16310199 | CHEMICAL COMPOSITION | December 2018 | June 2023 | Abandon | 54 | 4 | 1 | No | No |
| 16308567 | PROCESS FOR PREPARING PHARMACEUTICAL OPHTHALMIC COMPOSITIONS OF BRINZOLAMIDE | December 2018 | April 2021 | Abandon | 28 | 3 | 0 | No | No |
| 16195456 | IMMEDIATE/DELAYED DRUG DELIVERY | November 2018 | March 2021 | Allow | 28 | 2 | 1 | No | No |
| 16095309 | PREPARATION METHOD OF SUSTAINED-RELEASE MICROPARTICLES | October 2018 | March 2022 | Abandon | 41 | 4 | 1 | No | No |
| 16163182 | GRAPHENE-BASED MULTIFUNCTIONAL COSMETIC COMPOSITIONS | October 2018 | December 2021 | Abandon | 38 | 2 | 1 | No | No |
| 16094069 | NOVEL NANOEMULSIONS COMPRISING N-ACYL AMINO ACID SALT AND PROCESS FOR MAKING | October 2018 | August 2022 | Abandon | 46 | 4 | 1 | No | No |
| 16154855 | Foam Formulations Containing at Least One Triterpenoid | October 2018 | April 2021 | Abandon | 30 | 1 | 1 | No | No |
| 16091379 | NANOFIBROUS MAT CONTAINING CERAMIC PARTICLES WITH RELEASABLE DOPANT | October 2018 | April 2022 | Abandon | 42 | 1 | 1 | Yes | No |
| 16146237 | MODIFIED RELEASE FORMULATION OF LACOSAMIDE | September 2018 | January 2022 | Allow | 40 | 4 | 0 | No | No |
| 16144809 | COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | September 2018 | August 2020 | Abandon | 23 | 0 | 1 | No | No |
| 16086631 | BIOCOMPATIBLE ADHESIVES AND METHODS OF USE THEREOF | September 2018 | February 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16128597 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | September 2018 | July 2020 | Abandon | 22 | 0 | 1 | No | No |
| 16117549 | HAIR-TREATMENT COMPOSITIONS AND METHODS OF USE | August 2018 | June 2023 | Allow | 58 | 4 | 1 | Yes | No |
| 16079009 | DUAL-RATE RELEASE FORMULATION WITH HIGH DRUG LOADING | August 2018 | January 2022 | Abandon | 40 | 2 | 1 | No | No |
| 16107708 | INTERPENETRATING POLYMER NETWORK HYDROGEL | August 2018 | May 2023 | Allow | 57 | 4 | 1 | Yes | No |
| 16072046 | HYDROALCOHOLIC FOAM FORMULATIONS OF NAFTIFINE | July 2018 | March 2022 | Abandon | 44 | 3 | 1 | No | No |
| 16069979 | WATER-IN-OIL EMULSION COSMETIC MATERIAL | July 2018 | June 2021 | Allow | 35 | 2 | 0 | Yes | Yes |
| 16069692 | Depilatory Compositions Comprising Aminoalkylpropanol | July 2018 | October 2021 | Allow | 39 | 2 | 1 | Yes | No |
| 16033025 | INJECTABLE PREFORMED MACROSCOPIC 3-DIMENSIONAL SCAFFOLDS FOR MINIMALLY INVASIVE ADMINISTRATION | July 2018 | January 2023 | Abandon | 54 | 4 | 1 | No | No |
| 15987500 | ULTRAFINE NANOPARTICLES COMPRISING A FUNCTIONALIZED POLYORGANOSILOXANE MATRIX AND INCLUDING METAL COMPLEXES; METHOD FOR OBTAINING SAME AND USES THEREOF IN MEDICAL IMAGING AND/OR THERAPY | May 2018 | June 2022 | Allow | 49 | 4 | 1 | Yes | No |
| 15968461 | SURFACE MOUNTABLE DELIVERY DEVICE | May 2018 | January 2023 | Abandon | 56 | 3 | 1 | No | No |
| 15772769 | METHOD FOR ACCELERATING THE SUGAR-COATING FORMATION OF SUGAR ALCOHOL COATING WITH CALCIUM LACTATE | May 2018 | November 2022 | Abandon | 55 | 5 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KASSA, TIGABU.
With a 42.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KASSA, TIGABU works in Art Unit 1619 and has examined 676 patent applications in our dataset. With an allowance rate of 34.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner KASSA, TIGABU's allowance rate of 34.2% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KASSA, TIGABU receive 2.96 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KASSA, TIGABU is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +21.3% benefit to allowance rate for applications examined by KASSA, TIGABU. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 9.6% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.0% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 55.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 61.5% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 48.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 61.2% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.